Table II. Summary of the HRSV ligands identified with MS/MS analysis in persistently HRSV-infected cells.

Protein	Position	Sequence	HLA I	HLA Binding Affinityc
Fusion (F) protein	229–239	RLLEITREFSV	HLA-A*02:01	1 ± 1
Nucleoprotein (N)	315–323	TQFPHFSSV	HLA-A*02:01	0.4 ± 0.5
Non-structural protein 1 (NS1)	33–41	KLIHLTNAL	HLA-A*02:01	8 ± 1
Nucleoprotein (N)	306–314	NPKASLLSL	HLA-B*07:02	12 ± 6
Non-structural protein 2 (NS2)	19–30	RPLSLETTITSL	HLA-B*07:02	9 ± 6
Glycoprotein (G)	25–33	FISSGLYKL	HLA-C*07:02	N.D.
Nucleoprotein (N)	100–109	HRQDINGKEMa	HLA-B*27:05	26 ± 5
Nucleoprotein (N)	184–194	RRANNVLKNEMa	HLA-B*27:05	10 ± 1
Nucleoprotein (N)	195–205	KRYKGLLPKDIa	HLA-B*27:05	5 ± 2
Matrix (M)	76–84	SRSALLAQMa	HLA-B*27:05	9 ± 2
Matrix (M)	169–177	VRNKDLNTLa	HLA-B*27:05	12 ± 5
Polymerase (L)	2089–2097	GRNEVFSNKa	HLA-B*27:05	18 ± 3
Matrix 2–22k (M2)	150–159	KRLPADVLKKa	HLA-B*27:05	9 ± 2
Phosphoprotein (P)	198–208	LRNEESEKMAKa	HLA-B*27:05	14 ± 3
Non-structural protein 2 (NS2)	37–45	HRFIYLINHa	HLA-B*27:05	11 ± 4
Matrix (M)	188–198	AITNAKIIb	HLA-C*04:01	16 ± 12

^a From (17).

^b From (18).

^c HLA peptide binding is expressed as EC₅₀ (the molar concentration of the peptide at 50% of the maximum fluorescence obtained in a concentration range of 0.01–200 μm), and its standard deviation.